Sign Out
Fluconazol STELLA 150 mg is indicated in adults for the treatment of: Cryptococcal meningitis.
Coccidioidomycosis.
Mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.
Vaginal candidiasis, acute or recurrent; when local therapy is not appropriate.
Candidal balanitis when local therapy is not appropriate.
Dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated.
Tinea unguium (onychomycosis) when other agents are not considered appropriate.
Fluconazol STELLA 150 mg is indicated in adults for the prophylaxis of: Relapse of cryptococcal meningitis in patients with high risk of recurrence.
Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse.
To reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year).
Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation.
Fluconazol STELLA 150 mg is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old: Fluconazol STELLA 150 mg is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Fluconazol STELLA 150 mg can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence.
Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.
Consideration should be given to official guidance on the appropriate use of antifungals.
